Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Alimera Sciences revenue
Alimera Sciences's revenue is $80.8 million.
What is Alimera Sciences's revenue?
- Alimera Sciences's revenue growth from 2013 to 2023 is 4,213.78%.
- Alimera Sciences has 154 employees, and the revenue per employee ratio is $524,376.
- Alimera Sciences's peak quarterly revenue was $27.0M in 2024(q2).
- Alimera Sciences peak revenue was $80.8M in 2023.
- Alimera Sciences annual revenue for 2022 was 54.1M, -8.3% growth from 2021.
- Alimera Sciences annual revenue for 2023 was 80.8M, 49.19% growth from 2022.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Alimera Sciences historical revenue
Alimera Sciences's peak revenue was $80.8M in 2023. The peak quarterly revenue was $27.0M in 2024(q2).
Alimera Sciences's revenue increased from $1.9m in 2013 to $80.8M currently. That's a 4,213.78% change in annual revenue.
Alimera Sciences annual revenue
Alimera Sciences annual revenue over time
| Fiscal year / year | Alimera Sciences revenue |
|---|---|
| 2013 | $1.9M |
| 2014 | $8.4M |
| 2015 | $22.4M |
| 2016 | $34.3M |
| 2017 | $35.9M |
| 2018 | $46.6M |
| 2019 | $53.9M |
| 2020 | $50.8M |
| 2021 | $59.0M |
| 2022 | $54.1M |
| 2023 | $80.8M |
Rate Alimera Sciences' financial transparency
Alimera Sciences annual growth
Alimera Sciences saw the greatest revenue growth in 2014, when revenue increased by 349.95%.
Alimera Sciences had the lowest revenue growth in 2022, when revenue changed by -8.3%.
Alimera Sciences annual growth rate over time
| Year | Alimera Sciences growth |
|---|---|
| 2014 | 350%↑ |
| 2015 | 166%↑ |
| 2016 | 53%↑ |
| 2017 | 5%↑ |
| 2018 | 30%↑ |
| 2019 | 16%↑ |
| 2020 | -6%↓ |
| 2021 | 16%↑ |
| 2022 | -8%↓ |
| 2023 | 49%↑ |
Alimera Sciences quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Alimera Sciences quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2013 | - | $179,000 | $758,000 | $935,000 |
| 2014 | $2.1M | $2.2M | $2.4M | $1.7M |
| 2015 | $3.9M | $5.8M | $6.9M | $5.8M |
| 2016 | $5.8M | $9.6M | $8.3M | $10.7M |
| 2017 | $6.6M | $10.4M | $9.8M | $9.1M |
| 2018 | $9.6M | $10.7M | $11.1M | $15.1M |
| 2019 | $12.9M | $10.9M | $12.9M | $17.3M |
| 2020 | $14.5M | $10.0M | $12.5M | $13.8M |
| 2021 | $11.2M | $21.7M | $12.2M | $14.0M |
| 2022 | $11.9M | $14.6M | $13.6M | $14.0M |
| 2023 | $13.5M | $17.5M | $23.4M | $26.3M |
| 2024 | $23.0M | $27.0M | - | - |
Alimera Sciences jobs nearby
Do you work at Alimera Sciences?
Is Alimera Sciences transparent about its revenue structure?
Alimera Sciences financial information
| CEO | Richard S. Eiswirth |
| Industry | Health Care Equipment & Services |
| Company Type | Public |
| Employees Number | 154 |
| Date Founded | 2003 |
| Headquarters | Alpharetta, Georgia |
| Number of Locations | 1 |
| Revenue | $80.8M |
| Net Income | -$18,107,000 |
| Gross Proft | $69.9M (2023) |
| EBITDA | ($1.1M) (2023) |
| PE Ratio | -1.86 |
| Tax Rate | -0.0% |
| Market Capitalization | $37.4M |
| Total Assets | $42,602,000 |
| Ticker | ALIM |
Alimera Sciences jobs you might like
Alimera Sciences financing
Alimera Sciences received early financing of $26.8M on 2004-07-09.
| Series | Round size | Date |
|---|---|---|
| Series A | $26.8M | 07/2004 |
| Series B | $31.8M | 11/2005 |
| Series C | $30M | 03/2008 |
| Series C | $5M | 10/2009 |
| Post Ipo Equity | $40M | 07/2012 |
| Post Ipo Equity | $37.5M | 01/2014 |
| Post Ipo Debt | $35M | 04/2014 |
| Post Ipo Equity | $50M | 11/2014 |
| Post Ipo Equity | $26.5M | 08/2016 |
| Post Ipo Debt | $1.8M | 04/2020 |
| Post Ipo Equity | $20M | 04/2021 |
Alimera Sciences investors
| Investors | Security type |
|---|---|
| Polaris Partners | Series A |
| Intersouth Partners | Series A |
| Scale Venture Partners | Series A |
| Domain Associates | Series A |
| Polaris Partners | Series B |
| Intersouth Partners | Series B |
| Scale Venture Partners | Series B |
| Venrock | Series B |
| Domain Associates | Series B |
| Polaris Partners | Series C |
| Intersouth Partners | Series C |
| Scale Venture Partners | Series C |
| Venrock | Series C |
| Domain Associates | Series C |
| Polaris Partners | Series C |
| Intersouth Partners | Series C |
| Scale Venture Partners | Series C |
| Venrock | Series C |
| Domain Associates | Series C |
| New Enterprise Associates (NEA) | Post Ipo Equity |
| SOFINNOVA INVESTMENTS INC | Post Ipo Equity |
| Palo Alto Investors | Post Ipo Equity |
| HERCULES CAPITAL INC | Post Ipo Debt |
| Deerfield | Post Ipo Equity |
| Federal Government | Post Ipo Debt |
| Ocumension Therapeutics | Post Ipo Equity |
Alimera Sciences competitors
Alimera Sciences's top competitor, McKesson, earned an annual revenue of $309.0B.
Alimera Sciences's smallest competitor is Intersect ENT with revenue of $106.7M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 832 |
| Seagen | $85,008 | $2.0B | 900 | - |
| McKesson | $51,976 | $309.0B | 80,000 | 449 |
| Intuitive Surgical | $113,813 | $8.4B | 5,527 | 292 |
| Merck | $90,328 | $64.2B | 74,000 | 1,400 |
| Intersect ENT | $67,446 | $106.7M | 393 | - |
| Hospira | $64,435 | $4.5B | 19,000 | - |
| Stryker | $69,470 | $22.6B | 43,000 | 1,690 |
| Baxter International | $54,368 | $10.6B | 48,000 | 183 |
| Quidel | $71,489 | $1.7B | 1,500 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Alimera Sciences highest paying jobs
Zippia gives an in-depth look into the details of Alimera Sciences, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Alimera Sciences. The employee data is based on information from people who have self-reported their past or current employments at Alimera Sciences. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Alimera Sciences. The data presented on this page does not represent the view of Alimera Sciences and its employees or that of Zippia.
Alimera Sciences may also be known as or be related to ALIMERA SCIENCES INC, Alimera Sciences, Alimera Sciences Inc, Alimera Sciences Inc. and Alimera Sciences, Inc.